Amgen Inc. (AMGN)
$
287.71
+2.10 (0.73%)
Key metrics
Financial statements
Free cash flow per share
19.7119
Market cap
154.9 Billion
Price to sales ratio
4.4375
Debt to equity
7.5665
Current ratio
1.3056
Income quality
1.8149
Average inventory
6.7 Billion
ROE
0.9792
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
Amgen Inc. is a global biotechnology company that discovers, develops, manufactures, and delivers human therapeutics focusing on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience. The company reported an income before tax of $4,609,000,000.00 showcasing its pre-tax profitability. The EBITDA is $13,356,000,000.00 a key indicator of the company's operational profitability, while the operating income ratio is 0.22 indicating the company's operational profitability margin. Additionally, the gross profit ratio is 0.62 reflecting the efficiency of the company's production and sales operations. The company's stock is identified with the symbol 'AMGN' in the market, representing a significant asset for investors. Amgen's product portfolio includes treatments such as Enbrel for plaque psoriasis and rheumatoid arthritis, Neulasta for patients with low white blood cell counts due to cancer, Prolia for osteoporosis in postmenopausal women, and Repatha to reduce cardiovascular risks, among others. It also engages in several collaboration agreements to develop innovative therapies, such as its partnership with Novartis Pharma AG and Kyowa Kirin Co., Ltd. Trading at a price of $297.03 the stock is positioned in the higher-end market, reflecting the company's strong market presence. Furthermore, the stock has a high average trading volume of 2,242,174.00 indicating strong liquidity and investor interest. With a large market capitalization of $154,892,131,020.00 the company is a dominant player in the biotechnology industry, contributing significantly to the overall market landscape. Amgen Inc. operates within the Healthcare sector, driving innovation and growth through its cutting-edge research and product development. Its offerings, including Otezla, Aranesp, and KYPROLIS, illustrate its commitment to providing impactful therapies for various health conditions. By serving healthcare providers across multiple channels, including hospitals and pharmacies, Amgen focuses on delivering solutions that enhance patient outcomes. The company's collaborations with firms like Neumora Therapeutics and Plexium underscore its strategic approach to expanding its therapeutic portfolio, positioning it to remain a key player in a constantly evolving industry.
Is Amgen Inc. (AMGN) a good investment?
Investing in Amgen Inc. (AMGN) depends on multiple factors, including revenue growth, profit margins, debt-to-equity ratio, earnings per share, and return on equity. Analysts have rated it as B+, with a Bearish outlook. Always conduct your own research before investing.
What is Amgen Inc. (AMGN)'s stock forecast?
Analysts predict Amgen Inc. stock to fluctuate between $253.30 (low) and $339.17 (high) in the next 365 days, reflecting market expectations and potential volatility.
What is Amgen Inc.'s market capitalization?
As of 2025-08-29, Amgen Inc.'s market cap is $154,892,131,020, based on 538,362,000 outstanding shares.
How does Amgen Inc. compare to competitors like Eli Lilly & Co.?
Compared to Eli Lilly & Co., Amgen Inc. has a Lower Market-Cap, indicating a difference in performance.
Does Amgen Inc. pay dividends?
Amgen Inc. pays dividends. The current dividend yield is 3.20%, with a payout of $2.38 per share.
How can I buy Amgen Inc. (AMGN) stock?
To buy Amgen Inc. (AMGN) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for AMGN. Place an order (Market, Limit, etc.).
What is the best time to invest in Amgen Inc.?
The best time to invest depends on market trends and technical indicators, which show a Bearish trend based on economic conditions and company performance.
Has Amgen Inc. stock ever split?
Amgen Inc.'s last stock split was 2:1 on 1999-11-22.
How did Amgen Inc. perform in the last earnings report?
Revenue: $33,424,000,000 | EPS: $7.56 | Growth: -39.81%.
Where can I find Amgen Inc.'s investor relations reports?
Visit https://www.amgen.com/investor-relations for detailed financial reports.
Where can I find historical stock prices for Amgen Inc.?
You can explore historical data from here
What is the all-time high and low for Amgen Inc. stock?
All-time high: $346.85 (2024-07-25) | All-time low: $198.64 (2021-12-01).
What are the key trends affecting Amgen Inc. stock?
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
prnewswire.com
THOUSAND OAKS, Calif. , Aug. 29, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at the 2025 Wells Fargo Healthcare Conference at 10:15 a.m.
fool.com
The healthcare industry is a good place to look for strong dividend-paying stocks. Many companies in the sector offer products that are consistently in demand, regardless of the state of the economy.
zacks.com
Amgen's stock is up 13.5% in 2025, fueled by strong drug sales and new biosimilars, but looming competition and pricing headwinds pose challenges.
reuters.com
Royalty Pharma said on Monday it has signed a deal with BeOne Medicines to acquire a royalty interest in Amgen's drug for small cell lung cancer for up to $950 million.
globenewswire.com
NEW YORK, Aug. 25, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it has acquired a royalty interest in Amgen's Imdelltra, a first-in-class DLL3 targeting bispecific T-cell engager (BiTE), from BeOne Medicines for $885 million upfront. The agreement includes an option for BeOne to sell additional Imdelltra royalties to Royalty Pharma for up to $65 million within the next 12 months.
seekingalpha.com
Both Amgen (AMGN) and Johnson & Johnson (JNJ) recently received a 60-day ultimatum to lower their prices in the U.S. market. A fundamental analysis shows AMGN to be better positioned than JNJ to absorb drug pricing pressure. Both companies have robust profitability and R&D pipelines, but AMGN's growth record and PEGY ratio make it more appealing under current conditions.
zacks.com
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
zacks.com
AMGN posts strong Q2 results as Repatha, Evenity, Blincyto and rare disease drugs power broad-based volume gains.
benzinga.com
Amgen Inc. AMGN shares are trading lower on Wednesday, despite the company reporting second-quarter results that surpassed analyst expectations after markets closed on Tuesday.
seekingalpha.com
Amgen Inc. (NASDAQ:AMGN ) Q2 2025 Earnings Conference Call August 5, 2025 4:30 PM ET Company Participants & - Corporate Participant James E. Bradner - Executive Vice President of Research Development Justin G.
See all news
